G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating because — you guessed it — the unrelenting routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? Well, what can you do except fire up the coffee kettle and quaff some cups of stimulation. Cinnamon coffee roll is our flavor today, for those who track this sort of thing. Meanwhile, here are some tidbits. Hope you have a smashing day and keep us in mind if you hear anything interesting …

Novartis increased pressure on Roche’s aging roster of big-selling drugs by becoming the latest company to win European approval for a lower-price version of the Rituxan drug, Reuters tells us. The drug, which is used to treat blood cancer and immunological diseases and is also known as MabThera, racked up $7.5 billion in global sales in 2016 and costs tens of thousands per year.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine